Harrow, Inc. Proceeds from Issuance of Private Placement
Harrow, Inc. (HROW) reported Proceeds from Issuance of Private Placement of $9.22 million for the 12-month period ending 2016-12-31, per its 10-K filed 2018-03-08.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfPrivatePlacement · last filed 2018-03-08
- Harrow, Inc. proceeds from issuance of private placement for the quarter ending 2012-03-31 was $0.00.
- Harrow, Inc. proceeds from issuance of private placement for the quarter ending 2011-12-31 was $0.00.
- Harrow, Inc. proceeds from issuance of private placement for the quarter ending 2011-09-30 was $0.00.
- Harrow, Inc. proceeds from issuance of private placement for the quarter ending 2011-06-30 was $0.00.
- Harrow, Inc. proceeds from issuance of private placement for fiscal 2016 was $9.22M.
- Harrow, Inc. proceeds from issuance of private placement for fiscal 2012 was $7.93M.
- Harrow, Inc. proceeds from issuance of private placement for fiscal 2011 was $0.00.
- Harrow, Inc. proceeds from issuance of private placement for fiscal 2010 was $0.00.
| Period end | Proceeds from Issuance of Private Placement 0 month | Proceeds from Issuance of Private Placement 3 month | Proceeds from Issuance of Private Placement 6 month | Proceeds from Issuance of Private Placement 9 month | Proceeds from Issuance of Private Placement 12 month | Proceeds from Issuance of Private Placement 155 month | Proceeds from Issuance of Private Placement 158 month | Proceeds from Issuance of Private Placement 161 month | Proceeds from Issuance of Private Placement 164 month |
|---|---|---|---|---|---|---|---|---|---|
| 2016-12-31 | $9.22M 10-K · filed 2018-03-08 | ||||||||
| 2012-12-31 | $7.93M 10-K · filed 2013-03-18 | ||||||||
| 2012-04-25 | $7.93M 10-K · filed 2014-03-28 | ||||||||
| 2012-04-20 | $7.95M 10-K · filed 2014-03-28 | ||||||||
| 2012-03-31 | $0.00 10-Q · filed 2012-05-10 | $0.00 derived: sum of 2 quarters · filed 2012-05-10 | $0.00 derived: sum of 3 quarters · filed 2012-05-10 | $0.00 derived: sum of 4 quarters · filed 2012-05-10 | $7.78M 10-Q · filed 2012-05-10 | ||||
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-23 | $0.00 derived: sum of 2 quarters · filed 2012-02-23 | $0.00 derived: sum of 3 quarters · filed 2012-02-23 | $0.00 10-K · filed 2012-02-23 | $7.78M 10-K · filed 2012-02-23 | ||||
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-02-23 | $0.00 derived: sum of 2 quarters · filed 2012-02-23 | $0.00 10-Q · filed 2012-02-23 | $0.00 derived: sum of 4 quarters · filed 2012-05-10 | $7.78M 10-Q · filed 2012-02-23 | ||||
| 2011-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2012-02-23 | $0.00 10-Q · filed 2012-02-23 | $0.00 derived: sum of 3 quarters · filed 2012-05-10 | $0.00 derived: sum of 4 quarters · filed 2012-05-10 | $7.78M 10-Q · filed 2012-02-23 | ||||
| 2011-03-31 | $0.00 10-Q · filed 2012-05-10 | $0.00 derived: sum of 2 quarters · filed 2012-05-10 | $0.00 derived: sum of 3 quarters · filed 2012-05-10 | ||||||
| 2010-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-23 | $0.00 derived: sum of 2 quarters · filed 2012-02-23 | $0.00 10-K · filed 2012-02-23 | ||||||
| 2010-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-02-23 | $0.00 10-Q · filed 2012-02-23 | |||||||
| 2010-06-30 | $0.00 10-Q · filed 2012-02-23 | ||||||||
| 2008-12-31 | $3.94M 10-K · filed 2013-03-18 | ||||||||
| 2008-05-12 | $3.94M 10-K · filed 2014-03-28 | ||||||||
| 2007-12-31 | $3.84M 10-K · filed 2014-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |